JP2022542884A5 - - Google Patents

Info

Publication number
JP2022542884A5
JP2022542884A5 JP2022504569A JP2022504569A JP2022542884A5 JP 2022542884 A5 JP2022542884 A5 JP 2022542884A5 JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022542884 A5 JP2022542884 A5 JP 2022542884A5
Authority
JP
Japan
Prior art keywords
amino acid
acid position
pharmaceutical composition
fcrn antagonist
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022504569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542884A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043533 external-priority patent/WO2021016571A2/en
Publication of JP2022542884A publication Critical patent/JP2022542884A/ja
Publication of JP2022542884A5 publication Critical patent/JP2022542884A5/ja
Priority to JP2025051382A priority Critical patent/JP2025098167A/ja
Pending legal-status Critical Current

Links

JP2022504569A 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 Pending JP2022542884A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025051382A JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
US62/878,541 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025051382A Division JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Publications (2)

Publication Number Publication Date
JP2022542884A JP2022542884A (ja) 2022-10-07
JP2022542884A5 true JP2022542884A5 (enExample) 2023-07-31

Family

ID=72087159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504569A Pending JP2022542884A (ja) 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Country Status (13)

Country Link
US (1) US20210024620A1 (enExample)
EP (1) EP4004039A2 (enExample)
JP (2) JP2022542884A (enExample)
KR (1) KR20220038432A (enExample)
CN (1) CN114466663B (enExample)
AU (1) AU2020315925A1 (enExample)
BR (1) BR112022001255A2 (enExample)
CA (1) CA3148764A1 (enExample)
CO (1) CO2022001164A2 (enExample)
IL (1) IL290101A (enExample)
MX (1) MX2022001038A (enExample)
TW (1) TW202120539A (enExample)
WO (1) WO2021016571A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250042176A (ko) 2022-07-27 2025-03-26 아블린쓰 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
CN121443644A (zh) 2023-07-05 2026-01-30 阿布林克斯有限公司 用于治疗IgG相关疾病和障碍的改善的FcRn拮抗剂
CN122029191A (zh) 2023-08-23 2026-05-12 赛诺菲 基于ctla-4的溶酶体降解剂及其用途
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025144848A1 (en) * 2023-12-27 2025-07-03 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) * 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR102168731B1 (ko) * 2011-03-30 2020-10-23 추가이 세이야쿠 가부시키가이샤 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
SG10201800492PA (en) * 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CA2946430A1 (en) * 2014-06-12 2015-12-17 F. Hoffmann-La Roche Ag Method for selecting antibodies with modified fcrn interaction
EP3215528B1 (en) * 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
KR102720769B1 (ko) * 2015-03-09 2024-10-22 아르제넥스 비브이 FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CN111094335B (zh) * 2017-05-15 2022-08-23 罗切斯特大学 广泛中和的抗流感单克隆抗体及其用途
MX2020005981A (es) * 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
CA3089602A1 (en) * 2018-01-26 2019-08-01 Genzyme Corporation Fc variants with enhanced binding to fcrn and prolonged half-life

Similar Documents

Publication Publication Date Title
JP2025098167A5 (enExample)
JP7206303B2 (ja) 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体
US8323646B2 (en) Engineered anti-IL-13 antibodies, compositions, methods and uses
RU2732226C2 (ru) Конъюгаты антитело-финомер
JP7116736B2 (ja) 操作されたヘテロ二量体タンパク質
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
JP2010532764A5 (enExample)
JP2020520231A5 (enExample)
JP2021511830A5 (enExample)
JP2019504617A5 (enExample)
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2023502968A5 (enExample)
MX2010011761A (es) Anticuerpos para el factor que estimula la colonia del granulocito-macrofago.
JP2019525728A5 (enExample)
CA3193273A1 (en) Methods and compositions to treat autoimmune diseases and cancer
JP2011518857A5 (enExample)
KR20200106056A (ko) 자가면역 질환 및 암을 치료하기 위한 항-cxcl13 항체
JP2022542884A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
RU2019123112A (ru) Анти-il-5 антитела
JP2024504923A5 (enExample)
JP2025529796A (ja) Ｔａｃｉポリペプチドを含む融合タンパク質及びその使用
JP2025533393A (ja) 免疫調節剤のスクリーニングと調製方法
JP2025517120A5 (enExample)
JP2025026957A (ja) ＩＬ－１β受容体シグナル伝達に干渉する剤
JP2022523047A5 (enExample)